Welcome to BioMarket Group!

R&D

In this section you will find R&D market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 103 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction

  1. Wnt Signaling Pathway in Oncology Drug Pipeline Update 2012

    $1,370.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 89 companies plus partners who are today developing 88 Wnt pathway targeting drugs in 273 developmental projects in cancer across 97 different targets. In addition, there is 1 suspended drug and another 45 drugs where development has been ceased. Learn More

  2. Colorectal Cancer Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 289 companies plus partners who are today developing 374 drugs targeting colorectal cancer in development. across 213 different targets. In addition, there are 5 suspended drugs and another 157 drugs where development has been ceased. Learn More

  3. Analytical Tool - Lymphoma

    $4,295.00
    Published by BioSeeker Group on Feb 21st, 2012
    A unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development. Learn More

  4. Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2012

    $685.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 40 companies plus partners who are today developing 31 Hedgehog pathway targeting drugs in 123 developmental projects in cancer across 40 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More

  5. Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 207 companies plus partners who are today developing 264 Alpha6Beta4 integrin pathway targeting drugs in 848 developmental projects in cancer across 107 different targets. In addition, there is 1 suspended drug and another 125 drugs where development has been ceased. Learn More

  6. IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2012

    $685.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 50 companies plus partners who are today developing 42 IL-7 pathway targeting drugs in 155 developmental projects in cancer across 45 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More

  7. TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 237 companies plus partners who are today developing 288 TGF-beta receptor pathway targeting drugs in 815 developmental projects in cancer across 165 different targets. In addition, there are 2 suspended drugs and another 172 drugs where development has been ceased. Learn More

  8. IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 105 companies plus partners who are today developing 110 IL-5 pathway targeting drugs in 354 developmental projects in cancer across 100 different targets. In addition, there is 1 suspended drug and another 47 drugs where development has been ceased. Learn More

  9. Biologicals in Oncology Drug Pipeline Update 2012

    $3,425.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 669 companies plus partners who are today developing 1071 biological drugs in 2294 developmental projects in cancer across 408 different targets. In addition, there are 17 suspended drugs and another 676 drugs where development has been ceased. Learn More

  10. IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 135 companies plus partners who are today developing 159 IL-3 pathway targeting drugs in 510 developmental projects in cancer across 118 different targets. In addition, there are 2 suspended drugs and another 71 drugs where development has been ceased. Learn More

  11. Analytical Tool - Angiogenesis in Oncology

    $4,295.00
    Published by BioSeeker Group on Feb 21st, 2012
    The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More

  12. Nucleic Acid Therapies in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 204 companies plus partners who are today developing 229 nucleic acid therapy drugs in 520 developmental projects in cancer across 173 different targets. In addition, there are 7 suspended drugs and another 177 drugs where development has been ceased. Learn More

  13. Lung Cancer Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 333 companies plus partners who are today developing 426 lung cancer drugs in 507 developmental projects in cancer across 243 different targets. In addition, there are 9 suspended drugs and another 189 drugs where development has been ceased. Learn More

  14. IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2012

    $1,370.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 72 companies plus partners who are today developing 57 IL-1 pathway targeting drugs in 210 developmental projects in cancer across 63 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

  15. Analytical Tool - Breast Cancer

    $4,295.00
    Published by BioSeeker Group on Feb 21st, 2012
    The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Learn More

Items 1 to 15 of 103 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction

R&D

In this section you will find R&D market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 103 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction

  1. Wnt Signaling Pathway in Oncology Drug Pipeline Update 2012

    $1,370.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 89 companies plus partners who are today developing 88 Wnt pathway targeting drugs in 273 developmental projects in cancer across 97 different targets. In addition, there is 1 suspended drug and another 45 drugs where development has been ceased. Learn More

  2. Colorectal Cancer Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 289 companies plus partners who are today developing 374 drugs targeting colorectal cancer in development. across 213 different targets. In addition, there are 5 suspended drugs and another 157 drugs where development has been ceased. Learn More

  3. Analytical Tool - Lymphoma

    $4,295.00
    Published by BioSeeker Group on Feb 21st, 2012
    A unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development. Learn More

  4. Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2012

    $685.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 40 companies plus partners who are today developing 31 Hedgehog pathway targeting drugs in 123 developmental projects in cancer across 40 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More

  5. Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 207 companies plus partners who are today developing 264 Alpha6Beta4 integrin pathway targeting drugs in 848 developmental projects in cancer across 107 different targets. In addition, there is 1 suspended drug and another 125 drugs where development has been ceased. Learn More

  6. IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2012

    $685.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 50 companies plus partners who are today developing 42 IL-7 pathway targeting drugs in 155 developmental projects in cancer across 45 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More

  7. TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 237 companies plus partners who are today developing 288 TGF-beta receptor pathway targeting drugs in 815 developmental projects in cancer across 165 different targets. In addition, there are 2 suspended drugs and another 172 drugs where development has been ceased. Learn More

  8. IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 105 companies plus partners who are today developing 110 IL-5 pathway targeting drugs in 354 developmental projects in cancer across 100 different targets. In addition, there is 1 suspended drug and another 47 drugs where development has been ceased. Learn More

  9. Biologicals in Oncology Drug Pipeline Update 2012

    $3,425.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 669 companies plus partners who are today developing 1071 biological drugs in 2294 developmental projects in cancer across 408 different targets. In addition, there are 17 suspended drugs and another 676 drugs where development has been ceased. Learn More

  10. IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 135 companies plus partners who are today developing 159 IL-3 pathway targeting drugs in 510 developmental projects in cancer across 118 different targets. In addition, there are 2 suspended drugs and another 71 drugs where development has been ceased. Learn More

  11. Analytical Tool - Angiogenesis in Oncology

    $4,295.00
    Published by BioSeeker Group on Feb 21st, 2012
    The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More

  12. Nucleic Acid Therapies in Oncology Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 204 companies plus partners who are today developing 229 nucleic acid therapy drugs in 520 developmental projects in cancer across 173 different targets. In addition, there are 7 suspended drugs and another 177 drugs where development has been ceased. Learn More

  13. Lung Cancer Drug Pipeline Update 2012

    $2,050.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 333 companies plus partners who are today developing 426 lung cancer drugs in 507 developmental projects in cancer across 243 different targets. In addition, there are 9 suspended drugs and another 189 drugs where development has been ceased. Learn More

  14. IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2012

    $1,370.00
    Published by BioSeeker Group on Feb 21st, 2012
    BioSeeker Group have identified 72 companies plus partners who are today developing 57 IL-1 pathway targeting drugs in 210 developmental projects in cancer across 63 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

  15. Analytical Tool - Breast Cancer

    $4,295.00
    Published by BioSeeker Group on Feb 21st, 2012
    The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Learn More

Items 1 to 15 of 103 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction
Recently Viewed Products

  1. R&D Drug Pipeline Database: 1-Year Subscription

  2. Protein Kinase Therapeutics in Oncology - Where to Commercialize?

  3. Protein Drug Delivery: Penetrating a Growth Market

  4. Prostate Cancer Drug Pipeline Update 2012

  5. Pricing & Reimbursement Series:Medicare Part Ds progress so far

Recently Viewed Products

  1. R&D Drug Pipeline Database: 1-Year Subscription

  2. Protein Kinase Therapeutics in Oncology - Where to Commercialize?

  3. Protein Drug Delivery: Penetrating a Growth Market

  4. Prostate Cancer Drug Pipeline Update 2012

  5. Pricing & Reimbursement Series:Medicare Part Ds progress so far

My Cart

You have no items in your shopping cart.

Compare Products

You have no items to compare.

Newsletter

© BioMarket Group. All Rights Reserved.
BioSeeker Group and BioMarket Group are both trademarks of BioSeeker Group AB